Literature DB >> 19321618

Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.

Lachlan Gray1, Michael Roche, Melissa J Churchill, Jasminka Sterjovski, Anne Ellett, Pantelis Poumbourios, Shameem Sherieff, Shameem Sheffief, Bin Wang, Nitin Saksena, Damian F J Purcell, Steven Wesselingh, Anthony L Cunningham, Bruce J Brew, Dana Gabuzda, Paul R Gorry.   

Abstract

Most human immunodeficiency virus type 1 (HIV-1) strains isolated from the brain use CCR5 for entry into macrophages and microglia. Strains that use both CCR5 and CXCR4 for entry (R5X4 strains) have been identified in the brains of some individuals, but mechanisms underlying the persistence of R5X4 viruses compartmentalized between the brain and other tissue reservoirs are unknown. Here, we characterized changes in the HIV-1 envelope (Env) that enhance the tropism of R5X4 variants for brain or lymphoid tissue. R5X4 Envs derived from the brains of two individuals had enhanced CCR5 usage in fusion assays compared to R5X4 Envs derived from matched spleen or blood, which was associated with reduced dependence on specific residues in the CCR5 N terminus and extracellular loop 1 (ECL1) and ECL3 regions. In contrast, spleen/blood-derived Envs had enhanced CXCR4 usage compared to brain-derived Envs, which was associated with reduced dependence on residues in the CXCR4 N terminus and ECL2 region. Consequently, brain-derived Envs had preferential CCR5 usage for HIV-1 entry into the JC53 cell line, could use either CCR5 or CXCR4 for entry into monocyte-derived macrophages (MDM), and could use CCR5 (albeit inefficiently) for entry into peripheral blood mononuclear cells (PBMC), whereas the entry of spleen-derived Envs was CXCR4 dependent in all three cell types. Mutagenesis studies of Env amino acid variants influencing coreceptor usage showed that S306 in the gp120 V3 region of brain-derived Envs reduces dependence on the CCR5 N terminus and enhances CCR5 usage for HIV-1 entry into PBMC and MDM, whereas R306 in spleen-derived Envs reduces dependence on the CXCR4 N terminus and confers the CXCR4 restricted phenotype. These results identify mechanisms underlying R5X4 HIV-1 persistence in different tissue reservoirs. Tissue-specific changes in the gp120 V3 region that increase the efficiency of CCR5 or CXCR4 usage, and thereby influence coreceptor preference, may enhance the tropism of R5X4 strains for CCR5-expressing macrophage lineage cells in the brain and CXCR4-expressing T cells in lymphoid tissues, respectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321618      PMCID: PMC2681927          DOI: 10.1128/JVI.02648-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

Review 1.  The challenge of viral reservoirs in HIV-1 infection.

Authors:  Joel N Blankson; Deborah Persaud; Robert F Siliciano
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

2.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

3.  Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.

Authors:  E J Platt; S E Kuhmann; P P Rose; D Kabat
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity.

Authors:  P R Gorry; G Bristol; J A Zack; K Ritola; R Swanstrom; C J Birch; J E Bell; N Bannert; K Crawford; H Wang; D Schols; E De Clercq; K Kunstman; S M Wolinsky; D Gabuzda
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.

Authors:  Paul R Gorry; Joann Taylor; Geoffrey H Holm; Andrew Mehle; Tom Morgan; Mark Cayabyab; Michael Farzan; Hui Wang; Jeanne E Bell; Kevin Kunstman; John P Moore; Steven M Wolinsky; Dana Gabuzda
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.

Authors:  Emmanuel G Cormier; Tatjana Dragic
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.

Authors:  Jayaram R Tagat; Stuart W McCombie; Dennis Nazareno; Marc A Labroli; Yushi Xiao; Ruo W Steensma; Julie M Strizki; Bahige M Baroudy; Kathleen Cox; Jean Lachowicz; Geoffrey Varty; Robert Watkins
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

8.  Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype.

Authors:  Ingrid Karlsson; Liselotte Antonsson; Yu Shi; Monica Oberg; Anders Karlsson; Jan Albert; Björn Olde; Christer Owman; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS.

Authors:  Asa Ohagen; Amy Devitt; Kevin J Kunstman; Paul R Gorry; Patrick P Rose; Bette Korber; Joann Taylor; Robert Levy; Robert L Murphy; Steven M Wolinsky; Dana Gabuzda
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.

Authors:  Mark A Jensen; Fu-Sheng Li; Angélique B van 't Wout; David C Nickle; Daniel Shriner; Hong-Xia He; Sherry McLaughlin; Raj Shankarappa; Joseph B Margolick; James I Mullins
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  38 in total

1.  HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children.

Authors:  Michael J Boivin; Theodore D Ruel; Hannah E Boal; Paul Bangirana; Huyen Cao; Leigh A Eller; Edwin Charlebois; Diane V Havlir; Moses R Kamya; Jane Achan; Carolyne Akello; Joseph K Wong
Journal:  AIDS       Date:  2010-05-15       Impact factor: 4.177

Review 2.  Coreceptors and HIV-1 pathogenesis.

Authors:  Paul R Gorry; Petronela Ancuta
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

3.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Genetic signatures of HIV-1 envelope-mediated bystander apoptosis.

Authors:  Anjali Joshi; Raphael T C Lee; Jonathan Mohl; Melina Sedano; Wei Xin Khong; Oon Tek Ng; Sebastian Maurer-Stroh; Himanshu Garg
Journal:  J Biol Chem       Date:  2013-11-21       Impact factor: 5.157

5.  M-tropic HIV envelope protein gp120 exhibits a different neuropathological profile than T-tropic gp120 in rat striatum.

Authors:  Alessia Bachis; Maria I Cruz; Italo Mocchetti
Journal:  Eur J Neurosci       Date:  2010-07-28       Impact factor: 3.386

Review 6.  Bioinformatic analysis of HIV-1 entry and pathogenesis.

Authors:  Benjamas Aiamkitsumrit; Will Dampier; Gregory Antell; Nina Rivera; Julio Martin-Garcia; Vanessa Pirrone; Michael R Nonnemacher; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

7.  Activation of TRPML1 clears intraneuronal Aβ in preclinical models of HIV infection.

Authors:  Mihyun Bae; Neha Patel; Haoxing Xu; Mingwaoh Lee; Kumiko Tominaga-Yamanaka; Avindra Nath; Jonathan Geiger; Myriam Gorospe; Mark P Mattson; Norman J Haughey
Journal:  J Neurosci       Date:  2014-08-20       Impact factor: 6.167

8.  Neruodevelopmental Outcomes in Preschool Children Living With HIV-1 Subtypes A and D in Uganda.

Authors:  Horacio Ruiseñor-Escudero; Alla Sikorskii; Itziar Familiar-Lopez; Deborah Persaud; Carrie Ziemniak; Noeline Nakasujja; Robert Opoka; Michael Boivin
Journal:  Pediatr Infect Dis J       Date:  2018-12       Impact factor: 2.129

Review 9.  Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection.

Authors:  Gabriel Gras; Marcus Kaul
Journal:  Retrovirology       Date:  2010-04-07       Impact factor: 4.602

10.  Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5.

Authors:  Hamid Salimi; Michael Roche; Nicholas Webb; Lachlan R Gray; Kelechi Chikere; Jasminka Sterjovski; Anne Ellett; Steve L Wesselingh; Paul A Ramsland; Benhur Lee; Melissa J Churchill; Paul R Gorry
Journal:  J Leukoc Biol       Date:  2012-10-17       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.